



May 2026

## SMA Patient Organization and SMA Community Letter

### Dear SMA Community, Clinical Trial Participants, and Families,

We are thrilled to share an important milestone for the Spinal Muscular Atrophy (SMA) community. Recently, the final participant completed NMD Pharma's ([www.nmdpharma.com](http://www.nmdpharma.com)) Phase 2 SYNAPSE-SMA clinical trial with our investigational skeletal muscle activation enhancing drug therapy.

We would like to acknowledge the entire global SMA community for the extraordinary interest, encouragement, and willingness to spread awareness and excitement about our investigational drug ignaseclant (previously known as NMD670) and about this study.

If you took part in the clinical trial or reached out to a site with interest in participating, we extend our deepest gratitude. Your time, travel, and commitment represent a personal sacrifice – one made not only for yourselves or your families, but for the broader SMA community worldwide. The knowledge gained from your participation is invaluable, helping us better understand our investigational therapy, ignaseclant, and move forward to realize its potential to improve life for people living with SMA.

Thanks to your continued support, we successfully enrolled 52 participants with SMA Type 3 across study sites in the US and Europe. The goal of the study was to evaluate the efficacy, safety, tolerability and how the body processes the drug ignaseclant in the treatment of ambulatory adults with SMA Type 3.

### What's Next

Our team at NMD Pharma is working closely with investigators, data experts, and statisticians to ensure all study information is collected, verified, and analyzed to the highest scientific standards.

We anticipate being able to share an update with the entire SMA community on the outcomes of the SYNAPSE-SMA ignaseclant clinical trial after ensuring data quality, sometime in the middle or late summer.

If the results are positive, we will move forward, together, with the planning of the next (and potentially final) phase of clinical studies.

These next studies will be designed in collaboration with physicians, researchers, and most importantly, people living with SMA across diverse healthcare settings worldwide. We will also engage with regulators, including the US FDA and European Regulating Authorities, to align on the path toward making this potential new therapy available as soon as possible to all who may benefit.

From everyone at NMD Pharma, thank you for being part of this journey. Your courage, generosity, and partnership inspire our work every day. We are stronger together!

**Warm regards,**

### The NMD Pharma Team

NMD Pharma is a clinical-stage biotech company dedicated to enabling better lives through novel therapies designed to restore skeletal muscle health. Find out more about us online at [www.nmdpharma.com](http://www.nmdpharma.com) and follow us on Facebook at [www.facebook.com/nmdpharma](http://www.facebook.com/nmdpharma).